Full Text View
Tabular View
No Study Results Posted
Related Studies
Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes (RAPTIVA)
This study is ongoing, but not recruiting participants.
Study NCT00672204   Information provided by University of Minnesota
First Received: May 2, 2008   Last Updated: April 22, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Type 1 Diabetes Mellitus
Hypoglycemia
Additional conditions recognized in this trial
Diabetes Mellitus
Diabetes Mellitus, Type 1
More general conditions related to this trial
Autoimmune Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Immune System Diseases
Metabolic Diseases
Interventions listed in this trial
Raptiva
Sirolimus
anti-thymocyte globulin
Additional drug interventions recognized in this trial
Antilymphocyte Serum
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University of Minnesota
Juvenile Diabetes Research Foundation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services